Penn's Abramson Cancer Center
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk Popular GLP-1 weight-loss drugs may have an unexpected bonus: a significantly lower risk of breast cancer. - Date: - June 6, 2026 - Source: - University of Pennsylvania School of Medicine - Summary: - A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer.